MAX BioPharma, Inc. recently published two articles describing its anti-tumorigenic oxysterol lead compounds in the peer-reviewed journal, Cells....
MAX BioPharma Announces Update to its Oncology Program and Lead Drug Candidates
read more
News and Events
MAX BioPharma Publishes Follow Up Manuscript on its Oncology Program
MAX BioPharma scientists publish new paper titled "Inhibition of Non-Small Cell Lung Cancer Cells by Oxy210, an Oxysterol-Derivative that...
MAX BioPharma reports on novel oxysterol drug candidate for cancer
MAX BioPharma scientists publish new paper titled "Inhibition of Hedgehog Signaling in Fibroblasts, Pancreatic, and Lung Tumor Cells by Oxy186, an...
MAX BioPharma receives a Phase IIB award from the National Institute of Aging
MAX BioPharma is pleased to announce that it has been awarded a Phase IIB grant in continuation of the successful completion of our Phase II award...
MAX BioPharma selected to present at the LA BioMed Innovation Showcase
MAX BioPharma selected to present at the LA BioMed Innovation Showcase to be held on September 13th, 2018 in Manhattan Beach, California.